379 related articles for article (PubMed ID: 35337387)
1. Human placenta-derived amniotic epithelial cells as a new therapeutic hope for COVID-19-associated acute respiratory distress syndrome (ARDS) and systemic inflammation.
Babajani A; Moeinabadi-Bidgoli K; Niknejad F; Rismanchi H; Shafiee S; Shariatzadeh S; Jamshidi E; Farjoo MH; Niknejad H
Stem Cell Res Ther; 2022 Mar; 13(1):126. PubMed ID: 35337387
[TBL] [Abstract][Full Text] [Related]
2. Proposed Mechanisms of Targeting COVID-19 by Delivering Mesenchymal Stem Cells and Their Exosomes to Damaged Organs.
Jamshidi E; Babajani A; Soltani P; Niknejad H
Stem Cell Rev Rep; 2021 Feb; 17(1):176-192. PubMed ID: 33432484
[TBL] [Abstract][Full Text] [Related]
3. Hypothesis for the management and treatment of the COVID-19-induced acute respiratory distress syndrome and lung injury using mesenchymal stem cell-derived exosomes.
Taghavi-Farahabadi M; Mahmoudi M; Soudi S; Hashemi SM
Med Hypotheses; 2020 Nov; 144():109865. PubMed ID: 32562911
[TBL] [Abstract][Full Text] [Related]
4. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
Hashemian SR; Aliannejad R; Zarrabi M; Soleimani M; Vosough M; Hosseini SE; Hossieni H; Keshel SH; Naderpour Z; Hajizadeh-Saffar E; Shajareh E; Jamaati H; Soufi-Zomorrod M; Khavandgar N; Alemi H; Karimi A; Pak N; Rouzbahani NH; Nouri M; Sorouri M; Kashani L; Madani H; Aghdami N; Vasei M; Baharvand H
Stem Cell Res Ther; 2021 Jan; 12(1):91. PubMed ID: 33514427
[TBL] [Abstract][Full Text] [Related]
5. Application of human amniotic epithelial cells in regenerative medicine: a systematic review.
Zhang Q; Lai D
Stem Cell Res Ther; 2020 Oct; 11(1):439. PubMed ID: 33059766
[TBL] [Abstract][Full Text] [Related]
6. Stem cells and COVID-19: are the human amniotic cells a new hope for therapies against the SARS-CoV-2 virus?
Riedel RN; Pérez-Pérez A; Sánchez-Margalet V; Varone CL; Maymó JL
Stem Cell Res Ther; 2021 Mar; 12(1):155. PubMed ID: 33648582
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome.
Harrell CR; Jovicic BP; Djonov V; Volarevic V
Anal Cell Pathol (Amst); 2020; 2020():1939768. PubMed ID: 33274176
[TBL] [Abstract][Full Text] [Related]
8. [Advances on human amniotic epithelial cells and its clinical application potential].
Ji J; Yang L
Sheng Li Xue Bao; 2022 Feb; 74(1):80-92. PubMed ID: 35199129
[TBL] [Abstract][Full Text] [Related]
9. Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential.
Gorman E; Millar J; McAuley D; O'Kane C
Expert Rev Respir Med; 2021 Mar; 15(3):301-324. PubMed ID: 33172313
[No Abstract] [Full Text] [Related]
10. Understanding the pathophysiology of typical acute respiratory distress syndrome and severe COVID-19.
Ball L; Silva PL; Giacobbe DR; Bassetti M; Zubieta-Calleja GR; Rocco PRM; Pelosi P
Expert Rev Respir Med; 2022 Apr; 16(4):437-446. PubMed ID: 35341424
[TBL] [Abstract][Full Text] [Related]
11. Acute respiratory distress syndrome (ARDS) caused by the novel coronavirus disease (COVID-19): a practical comprehensive literature review.
Montenegro F; Unigarro L; Paredes G; Moya T; Romero A; Torres L; López JC; González FEJ; Del Pozo G; López-Cortés A; Diaz AM; Vasconez E; Cevallos-Robalino D; Lister A; Ortiz-Prado E
Expert Rev Respir Med; 2021 Feb; 15(2):183-195. PubMed ID: 32902367
[TBL] [Abstract][Full Text] [Related]
12. Stem Cell Extracellular Vesicles as Anti-SARS-CoV-2 Immunomodulatory Therapeutics: A Systematic Review of Clinical and Preclinical Studies.
Ahmed SH; AlMoslemany MA; Witwer KW; Tehamy AG; El-Badri N
Stem Cell Rev Rep; 2024 May; 20(4):900-930. PubMed ID: 38393666
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
Kuba K; Yamaguchi T; Penninger JM
Front Immunol; 2021; 12():732690. PubMed ID: 35003058
[TBL] [Abstract][Full Text] [Related]
14. Effect of early treatment with polyvalent immunoglobulin on acute respiratory distress syndrome associated with SARS-CoV-2 infections (ICAR trial): study protocol for a randomized controlled trial.
Mazeraud A; Gonçalves B; Aegerter P; Mancusi L; Rieu C; Bozza F; Sylla K; Siami S; Sharshar T
Trials; 2021 Feb; 22(1):170. PubMed ID: 33648563
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects.
Smadja DM; Mentzer SJ; Fontenay M; Laffan MA; Ackermann M; Helms J; Jonigk D; Chocron R; Pier GB; Gendron N; Pons S; Diehl JL; Margadant C; Guerin C; Huijbers EJM; Philippe A; Chapuis N; Nowak-Sliwinska P; Karagiannidis C; Sanchez O; Kümpers P; Skurnik D; Randi AM; Griffioen AW
Angiogenesis; 2021 Nov; 24(4):755-788. PubMed ID: 34184164
[TBL] [Abstract][Full Text] [Related]
16. The Promise of Mesenchymal Stem Cells Therapy for Acute Respiratory Distress Syndrome Caused by COVID-19.
Gu J; Zhao Q; Han Z; Han Z
Curr Stem Cell Res Ther; 2021; 16(3):277-285. PubMed ID: 32729428
[TBL] [Abstract][Full Text] [Related]
17. The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect.
Can A; Coskun H
Stem Cells Transl Med; 2020 Nov; 9(11):1287-1302. PubMed ID: 32779878
[TBL] [Abstract][Full Text] [Related]
18. Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial.
Monsel A; Hauw-Berlemont C; Mebarki M; Heming N; Mayaux J; Nguekap Tchoumba O; Diehl JL; Demoule A; Annane D; Marois C; Demeret S; Weiss E; Voiriot G; Fartoukh M; Constantin JM; Mégarbane B; Plantefève G; Malard-Castagnet S; Burrel S; Rosenzwajg M; Tchitchek N; Boucher-Pillet H; Churlaud G; Cras A; Maheux C; Pezzana C; Diallo MH; Ropers J; Menasché P; Larghero J;
Crit Care; 2022 Feb; 26(1):48. PubMed ID: 35189925
[TBL] [Abstract][Full Text] [Related]
19. Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients with Acute Respiratory Distress Syndrome (ARDS).
Lanzoni G; Linetsky E; Correa D; Alvarez RA; Marttos A; Hirani K; Cayetano SM; Castro JG; Paidas MJ; Efantis Potter J; Xu X; Glassberg M; Tan J; Patel AN; Goldstein B; Kenyon NS; Baidal D; Alejandro R; Vianna R; Ruiz P; Caplan AI; Ricordi C
CellR4 Repair Replace Regen Reprogram; 2020; 8():. PubMed ID: 34164564
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 immunopathology with emphasis on Th17 response and cell-based immunomodulation therapy: Potential targets and challenges.
Pourgholaminejad A; Pahlavanneshan S; Basiri M
Scand J Immunol; 2022 Feb; 95(2):e13131. PubMed ID: 34936112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
